You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東莞控股(000828.SZ):莞之光投資基金以1億元投資擬IPO的東陽光藥業
格隆匯 05-26 21:08

格隆匯5月26日丨東莞控股(000828.SZ)公吿,目前,莞之光投資基金已在市場監督管理局辦理註冊登記,並完成中國證券投資基金業協會私募投資基金的備案手續。金信資本已向莞之光投資基金出資人民幣3,000萬元,持有29.7%的份額。

5月25日,莞之光投資基金對廣東東陽光藥業有限公司進行了投資,投資金額合計人民幣1億元。東陽光藥業成立於2003年12月,是一家以小分子創新藥、生物創新藥和類似藥以及首仿藥和創新制劑的研發、臨牀前及臨牀開發為核心的醫藥創新研發型企業。東陽光藥業擁有科技部認證的抗感染新藥開發國家重點實驗室,承擔多項國家重大專項的研發,已經申請的專利超過1500多項,申請國外專利400多項。

目前東陽光藥業在研管線包括50個1類新藥項目,7個生物類似藥項目,72個仿製藥和創新劑項目。東陽光藥業本次擬通過引入戰略投資者、資產整合、股改,並實現IPO。

本次金信資本間接投資東陽光藥業,有利於優化投資結構,增加投資收益水平。目前東陽光藥業本輪引入戰略投資者的工作尚在開展中,莞之光投資基金最終投資持股比例等信息,公司將根據後續投資情況及時披露進展公吿。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account